April 2024
1. SADOWSKI M, Zabczyk M, Undas A
   Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide.
   J Thromb Thrombolysis. 2024 Apr 21. doi: 10.1007/s11239-024-02980.
   

   >> Share

   
   
2. MURAKAMI Y, Todo K, Uchida K, Yamagami H, et al
   One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke.
   J Thromb Thrombolysis. 2024;57:622-629.
   

   >> Share

   
   
3. MWITA JC, Francis JM, Pillay C, Ogah OS, et al
   Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
   J Thromb Thrombolysis. 2024;57:613-621.
   

   >> Share

   
   
4. AKHAN O, Boz M, Guzel T, Kis M, et al
   Discrimination of the acute pulmonary embolism subtypes based on the novel MAPH score.
   J Thromb Thrombolysis. 2024;57:683-690.
   

   >> Share

   
   March 2024
5. TRUONG B, Hornsby L, Fox B, Chou C, et al
   Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.
   J Thromb Thrombolysis. 2024 Mar 20. doi: 10.1007/s11239-024-02958.
   

   >> Share

   
   February 2024
6. GJERMENI D, Anfang V, Vetter H, Szabo S, et al
   Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study.
   J Thromb Thrombolysis. 2024 Feb 12. doi: 10.1007/s11239-023-02937.
   

   >> Share

   
   
7. ZHOU Q, Liu X, Gu ZC, Yang X, et al
   Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis.
   J Thromb Thrombolysis. 2024;57:194-203.
   

   >> Share

   
   January 2024
8. DE LUCENA LA, Freitas MAA, Souza AKC, Silva CHA, et al
   Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
   J Thromb Thrombolysis. 2024 Jan 28. doi: 10.1007/s11239-023-02945.
   

   >> Share

   
   
9. TRILLER DM, Wilson AS, Allen AL, Burnett AE, et al
   Digital dashboards for direct oral anticoagulant surveillance, intervention and operational efficiency: uptake, obstacles, and opportunities.
   J Thromb Thrombolysis. 2024;57:107-116.
   

   >> Share

   
   December 2023
10. D'ANNA L, Ornello R, Foschi M, Romoli M, et al
    Outcomes of mechanical thrombectomy in acute stroke patients with atrial fibrillation detected after stroke versus known atrial fibrillation.
    J Thromb Thrombolysis. 2023 Dec 21. doi: 10.1007/s11239-023-02923.
    

    >> Share

    
    
11. SALMASI S, Safari A, De Vera MA, Hogg T, et al
    Adherence to direct or vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a long-term observational study.
    J Thromb Thrombolysis. 2023 Dec 16. doi: 10.1007/s11239-023-02921.
    

    >> Share

    
    November 2023
12. MIZOBUCHI S, Kojima K, Miyagawa M, Tanaka Y, et al
    Association between aortic thrombi detected using non-obstructive general angioscopy and atrial fibrillation.
    J Thromb Thrombolysis. 2023 Nov 28. doi: 10.1007/s11239-023-02917.
    

    >> Share

    
    
13. WESTREICH R, Tsaban G, Barrett O, Kezerle L, et al
    Estimated glomerular filtration rate and the risk of stroke in individuals with diabetes mellitus and atrial fibrillation insight from a large contemporary population study.
    J Thromb Thrombolysis. 2023 Nov 9. doi: 10.1007/s11239-023-02913.
    

    >> Share

    
    October 2023
14. LEIVA O, How J, Grevet J, Brunner A, et al
    In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database.
    J Thromb Thrombolysis. 2023 Oct 15. doi: 10.1007/s11239-023-02900.
    

    >> Share

    
    
15. LIU G, Chen T, Zhang X, Hu B, et al
    Causal effect of atrial fibrillation on pulmonary embolism: a mendelian randomization study.
    J Thromb Thrombolysis. 2023 Oct 15. doi: 10.1007/s11239-023-02903.
    

    >> Share

    
    
16. DING WY, Fawzy AM, Romiti GF, Proietti M, et al
    Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
    J Thromb Thrombolysis. 2023 Oct 9. doi: 10.1007/s11239-023-02904.
    

    >> Share

    
    September 2023
17. LILJA J, Sjalander A, Sjalander S
    Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants.
    J Thromb Thrombolysis. 2023 Sep 13. doi: 10.1007/s11239-023-02890.
    

    >> Share

    
    August 2023
18. LIN Y, Chao TF, Tsai ML, Tseng CJ, et al
    Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
    J Thromb Thrombolysis. 2023 Aug 21. doi: 10.1007/s11239-023-02885.
    

    >> Share

    
    
19. RUSIN G, Konieczynska M, Natorska J, Malinowski KP, et al
    Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation.
    J Thromb Thrombolysis. 2023 Aug 19. doi: 10.1007/s11239-023-02878.
    

    >> Share

    
    
20. DING WY, Fawzy AM, Romiti GF, Proietti M, et al
    Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
    J Thromb Thrombolysis. 2023 Aug 11. doi: 10.1007/s11239-023-02866.
    

    >> Share

    
    
21. ATWATER BD, Guo JD, Keshishian A, Delinger R, et al
    Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Aug 2. doi: 10.1007/s11239-023-02838.
    

    >> Share

    
    
22. ATWATER BD, Di Fusco M, Keshishian A, Delinger R, et al
    Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Aug 2. doi: 10.1007/s11239-023-02855.
    

    >> Share

    
    July 2023
23. JIANG M, Wang C, Zhang Y
    Comparison of early and delayed anticoagulation therapy after ischemic stroke in patients with atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2023 Jul 28. doi: 10.1007/s11239-023-02872.
    

    >> Share

    
    
24. HSU CC, Chen CC, Chou CY, Chen KH, et al
    Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease.
    J Thromb Thrombolysis. 2023 Jul 15. doi: 10.1007/s11239-023-02859.
    

    >> Share

    
    
25. BRANCO DR, Alves M, Severiano E Sousa C, Costa J, et al
    Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis.
    J Thromb Thrombolysis. 2023 Jul 5. doi: 10.1007/s11239-023-02843.
    

    >> Share

    
    
26. HAYAT A, Sjalander A, Wallvik J
    Direct oral anticoagulants: patient reported adherence and minor bleedings.
    J Thromb Thrombolysis. 2023;56:55-64.
    

    >> Share

    
    June 2023
27. VIRK ZM, Richardson TL, Al-Samkari H
    Antithrombotic therapy for atrial fibrillation in hereditary hemorrhagic telangiectasia.
    J Thromb Thrombolysis. 2023 Jun 20. doi: 10.1007/s11239-023-02839.
    

    >> Share

    
    May 2023
28. IKENOUCHI H, Koge J, Tanaka T, Yamaguchi E, et al
    P-wave terminal force in lead V(1) and atrial fibrillation burden in cryptogenic stroke with implantable loop recorders.
    J Thromb Thrombolysis. 2023 May 2. doi: 10.1007/s11239-023-02816.
    

    >> Share

    
    
29. TRAN E, Ledbetter LE
    A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy.
    J Thromb Thrombolysis. 2023;55:721-728.
    

    >> Share

    
    April 2023
30. WANG X, Wen D, Chen Y, You C, et al
    Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation.
    J Thromb Thrombolysis. 2023 Apr 6. doi: 10.1007/s11239-023-02804.
    

    >> Share

    
    March 2023
31. CEREJA F, Alves M, Ferreira JJ, Caldeira D, et al
    Atrial fibrillation risk on Parkinson's disease - a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2023 Mar 25. doi: 10.1007/s11239-023-02792.
    

    >> Share

    
    
32. BERTEOTTI M, Gori AM, Giusti B, Fortini A, et al
    Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
    J Thromb Thrombolysis. 2023 Mar 11. doi: 10.1007/s11239-023-02784.
    

    >> Share

    
    February 2023
33. CLINE L, Generoso EMG, D'Apice N, Dellinger SK, et al
    Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min.
    J Thromb Thrombolysis. 2023;55:355-364.
    

    >> Share

    
    
34. SIEGAL DM, Freedman D, Ansell J
    Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
    J Thromb Thrombolysis. 2023;55:197-202.
    

    >> Share

    
    
35. COSTA LSD, Alsultan MM, Hincapie AL, Guo JJ, et al
    Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
    J Thromb Thrombolysis. 2023;55:339-345.
    

    >> Share

    
    January 2023
36. DECAMILLO D, Haymart B, Kong X, Kaatz S, et al
    Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 30. doi: 10.1007/s11239-023-02777.
    

    >> Share

    
    
37. JANSSON M, Sjalander S, Sjogren V, Bjorck F, et al
    Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    J Thromb Thrombolysis. 2023 Jan 6. doi: 10.1007/s11239-022-02763.
    

    >> Share

    
    
38. WANG K, Lu Y, Simegn MA, Xue H, et al
    Use of SAMe-TT(2)R(2) in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation.
    J Thromb Thrombolysis. 2023;55:175-180.
    

    >> Share

    
    
39. FELDEISEN D, Alexandris-Souphis C, Haymart B, Gu X, et al
    Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin.
    J Thromb Thrombolysis. 2023;55:141-148.
    

    >> Share

    
    
40. POLZIN A, Helten C, Metzen D, Zako S, et al
    TAVR: nemesis of NOACs?
    J Thromb Thrombolysis. 2023;55:181-184.
    

    >> Share

    
    
41. AMIRTABAR A, Vazquez SR, Saunders J, Witt DM, et al
    Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.
    J Thromb Thrombolysis. 2023;55:185-188.
    

    >> Share

    
    December 2022
42. WANG M, Yang Y, Luan M, Wang Y, et al
    Role of cerebral microbleeds in acute ischemic stroke and atrial fibrillation.
    J Thromb Thrombolysis. 2022 Dec 26. doi: 10.1007/s11239-022-02761.
    

    >> Share

    
    
43. HANTRAKUN N, Wongcharoen W, Thiankhaw K, Norasetthada L, et al
    Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
    J Thromb Thrombolysis. 2022 Dec 9. doi: 10.1007/s11239-022-02747.
    

    >> Share

    
    
44. CARBONE A, Bottino R, Attena E, Parisi V, et al
    Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia.
    J Thromb Thrombolysis. 2022 Dec 6. doi: 10.1007/s11239-022-02740.
    

    >> Share

    
    November 2022
45. LIANOS I, Varlamos C, Benetou DR, Mantis C, et al
    Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
    J Thromb Thrombolysis. 2022 Nov 12. pii: 10.1007/s11239-022-02723.
    

    >> Share

    
    October 2022
46. YE TTS, Siah QZ, Tan BYQ, Ho JSY, et al
    Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2022 Oct 3. pii: 10.1007/s11239-022-02713.
    

    >> Share

    
    September 2022
47. SERRAO A, Malfona F, Assanto GM, Orellana MGC, et al
    Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.
    J Thromb Thrombolysis. 2022 Sep 20. pii: 10.1007/s11239-022-02702.
    

    >> Share

    
    June 2022
48. NOVAK AR, Shakowski C, Trujillo TC, Wright GC, et al
    Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2022 Jun 10. pii: 10.1007/s11239-022-02668.
    

    >> Share

    
    May 2022
49. LIP GYH, Keshishian A, Kang A, Luo X, et al
    Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
    J Thromb Thrombolysis. 2022 May 17. pii: 10.1007/s11239-022-02660.
    

    >> Share

    
    April 2022
50. MARTINEZ KA, Eckman MH, Pappas MA, Rothberg MB, et al
    Prescribing of anticoagulation for atrial fibrillation in primary care.
    J Thromb Thrombolysis. 2022 Apr 21. pii: 10.1007/s11239-022-02655.
    

    >> Share

    
    
51. DING WY, Rivera-Caravaca JM, Marin F, Roldan V, et al
    Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.
    J Thromb Thrombolysis. 2022 Apr 15. pii: 10.1007/s11239-022-02638.
    

    >> Share

    
    
52. FROL S, Hudnik LK, Sernec LP, Sabovic M, et al
    Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status.
    J Thromb Thrombolysis. 2022;53:607-615.
    

    >> Share

    
    
53. DECAMILLO D, Haymart B, Barnes GD
    Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    J Thromb Thrombolysis. 2022;53:601-606.
    

    >> Share

    
    February 2022
54. POTERE N, Candeloro M, Porreca E, Marinari S, et al
    Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
    J Thromb Thrombolysis. 2022;53:346-351.
    

    >> Share

    
    
55. MEADOR S, Dyke S, Togami J, Kuskov B, et al
    Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.
    J Thromb Thrombolysis. 2022;53:436-445.
    

    >> Share

    
    
56. GALLI M, Gargiulo G
    Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment.
    J Thromb Thrombolysis. 2022;53:495-498.
    

    >> Share

    
    January 2022
57. BAI Y, Liu XY, Liu Y, Guo SD, et al
    Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.
    J Thromb Thrombolysis. 2022 Jan 24. pii: 10.1007/s11239-021-02622.
    

    >> Share

    
    October 2021
58. LV WH, Dong JZ, Du X, Hu R, et al
    Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    J Thromb Thrombolysis. 2021 Oct 22. pii: 10.1007/s11239-021-02588.
    

    >> Share

    
    
59. BEWERSDORF JP, Parmar N, Israel GM, Gettinger SN, et al
    Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
    J Thromb Thrombolysis. 2021;52:854-862.
    

    >> Share

    
    
60. CHEN Y, Zhang Y, Qu L, Huang W, et al
    Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    J Thromb Thrombolysis. 2021;52:872-879.
    

    >> Share

    
    
61. NISLY SA, Mihm AE, Gillette C, Davis KA, et al
    Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:817-827.
    

    >> Share

    
    
62. SADIQ H, Hoque L, Shi Q, Manning G, et al
    SUPPORT-AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF.
    J Thromb Thrombolysis. 2021;52:808-816.
    

    >> Share

    
    September 2021
63. PAPANASTASIOU A, Kartas A, Samaras A, Vrana E, et al
    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 25. pii: 10.1007/s11239-021-02571.
    

    >> Share

    
    
64. WANG CL, Wu VC, Tu HT, Huang YT, et al
    Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 23. pii: 10.1007/s11239-021-02570.
    

    >> Share

    
    
65. OBI CA, Bulsara K, Izard S, Delicce A, et al
    Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall.
    J Thromb Thrombolysis. 2021 Sep 4. pii: 10.1007/s11239-021-02555.
    

    >> Share

    
    
66. CHEN J, Zhou M, Wang H, Zheng Z, et al
    Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score.
    J Thromb Thrombolysis. 2021 Sep 2. pii: 10.1007/s11239-021-02554.
    

    >> Share

    
    August 2021
67. MENDOZA PA, McIntyre WF, Belley-Cote EP, Wang J, et al
    Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
    J Thromb Thrombolysis. 2021 Aug 2. pii: 10.1007/s11239-021-02530.
    

    >> Share

    
    
68. AFZAL S, Zaidi STR, Merchant HA, Babar ZU, et al
    Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.
    J Thromb Thrombolysis. 2021;52:646-653.
    

    >> Share

    
    
69. ROMOLI M, Marchetti G, Bernardini F, Urbinati S, et al
    Switching between direct oral anticoagulants: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:560-566.
    

    >> Share

    
    
70. BASS ME, Kiser TH, Page RL 2nd, McIlvennan CK, et al
    Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.
    J Thromb Thrombolysis. 2021;52:517-522.
    

    >> Share

    
    July 2021
71. LI RJ, Caughey GE, Shakib S
    Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jul 24. pii: 10.1007/s11239-021-02528.
    

    >> Share

    
    
72. KAO CC, Wang T, Parulekar AD
    Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.
    J Thromb Thrombolysis. 2021;52:232-238.
    

    >> Share

    
    
73. ROSSIER C, Spoutz P, Schaefer M, Allen A, et al
    Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management.
    J Thromb Thrombolysis. 2021;52:200-208.
    

    >> Share

    
    
74. WALLVIK N, Renlund H, Sjalander A
    Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    J Thromb Thrombolysis. 2021;52:315-323.
    

    >> Share

    
    
75. SYLVESTER KW, Wagner C, Lewin A, Fanikos J, et al
    Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience.
    J Thromb Thrombolysis. 2021;52:158-160.
    

    >> Share

    
    June 2021
76. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    

    >> Share

    
    May 2021
77. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    

    >> Share

    
    
78. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    

    >> Share

    
    
79. GUNER A, Kalcik M, Gunduz S, Gursoy MO, et al
    The relationship between incomplete surgical obliteration of the left atrial appendage and thromboembolic events after mitral valve surgery (from the ISOLATE Registry).
    J Thromb Thrombolysis. 2021;51:1078-1089.
    

    >> Share

    
    
80. MARCATTO L, Boer B, Sacilotto L, Olivetti N, et al
    Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.
    J Thromb Thrombolysis. 2021;51:1043-1049.
    

    >> Share

    
    April 2021
81. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    

    >> Share

    
    
82. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    

    >> Share

    
    February 2021
83. GAVIN O, Grandes J, Garcia MA, Marzo C, et al
    Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain.
    J Thromb Thrombolysis. 2021;51:475-484.
    

    >> Share

    
    January 2021
84. NABAVIZADEH P, Steen DL
    Highlights from the European society of cardiology congress 2020.
    J Thromb Thrombolysis. 2021;51:232-236.
    

    >> Share

    
    July 2020
85. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share